|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||-0.35|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Categories: Yahoo FinanceGet free summary analysis Northwest Biotherapeutics, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Northwest Biotherapeutics, Inc. – Celldex Therapeutics, Inc., Argos Therapeutics, Inc., Stemline Therapeutics, Inc., Agenus Inc., Amgen Inc., Progenics Pharmaceuticals, Inc., Merck & Co., Inc. and ImmunoCellular Therapeutics, Ltd. ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Northwest Biotherapeutics, Inc. reports financial results for the quarter ended December 31, 2016. Highlights Summary numbers: Revenues of USD 0.07 million, Net Earnings of USD -30.71 million. Change in operating cash flow of 36.29% compared to same period last year is about the same as change in earnings, likely no significant ... Read more (Read more...)
Imagine a derailed freight train carrying dumpsters on fire. That's an accurate description of the Northwest Bio 10-K filed Monday night.